Chromocell Therapeutics Corp. (CHRO): Earnings growth forecast for next year
Chromocell Therapeutics is advancing neuromedicine. The projected net profit trend demonstrates that the metric level is 0.00. Robotic systems are accelerating neuron screening by eliminating routine tasks. The company is implementing green chemistry principles in the development of analgesics while adhering to bioethics. The current environmental status is limited to basic waste disposal, which is typical for startups without their own manufacturing plants.
Comprehensive metric breakdowns and analytics for chromocell.com (CHRO)
- price and consensus price forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- company liabilities and liquidity data:
Debt to Equity Chromocell Therapeutics|CHRO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Chromocell Therapeutics Corp.|CHRO - Aggregate Debt Obligations|Debt to Book Value Chromocell Therapeutics|CHRO - Amount of Long-Term Liabilities|Company Short-Term Debts Chromocell Therapeutics|Quick Ratio chromocell.com
- earnings and valuation multiples information:
CHRO - Company Net Income|Expected Profit Chromocell Therapeutics|CHRO - Company Value to Net Income|Forward P/E Multiple Chromocell Therapeutics|CHRO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Chromocell Therapeutics|CHRO - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Chromocell Therapeutics|CHRO - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months chromocell.com|CHRO - Earnings growth in current year|Expected earnings per share growth for next year Chromocell Therapeutics
- total revenue and sales volume data:
Fundamental company valuation:Chromocell Therapeutics Corporation
This indicator measures the expected earnings per share trend, reflecting the analysts' consensus forecast for the business's future profitability. By analyzing the forward EPS dynamics model of Chromocell Therapeutics (CHRO), an investor can assess the stability of Chromocell Therapeutics' earnings, which directly depends on the efficiency of exclusive contracts with international CRO vendors for the outsourcing of complex compound synthesis.
Direct competitors
Net earnings per share growth forecast for next year Biogen Corp|Expected net earnings per share growth next year Neurocrine Corp NBIX|Earnings growth forecast for next year RGC|Expected earnings per share growth for next year axsome.com AXSM|Earnings growth forecast for next year ACAD (ACADIA Pharmaceuticals Inc.)|Xenon Pharmaceuticals Inc. (XENE) - Expected net earnings per share growth next year|VKTX - Net earnings per share growth forecast for next year|SUPN: Net earnings per share growth forecast for next year|Catalyst Pharmaceuticals (CPRX) - Net earnings per share growth forecast for next year|DNLI (denalitherapeutics.com) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year HRMY|BHVN: Expected earnings per share trend next year|Expected earnings per share growth for next year AMLX (Amylyx)|Projected earnings per share increase next year TRVI|Earnings growth forecast for next year PRAX (Praxis Precision Medicines)|Expected earnings per share trend next year AVXL|CeriBell - Earnings growth forecast for next year|Expected net earnings per share growth next year Prothena Corporation plc|alector.com (ALEC) - Net earnings per share growth forecast for next year|Annexon Biosciences Inc. - Expected earnings per share trend next year|OMER (Omeros Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year neurogene.com|Net earnings per share growth forecast for next year AC Immune SA (ACIU)|VYGR: Net earnings per share change forecast for next year|Earnings growth forecast for next year NMRA (Neumora Therapeutics Inc)|Scilex Holding Company, Inc. (SCLX) - Expected net earnings per share growth next year|TVGN: Expected earnings per share growth for next year|ACOG - Earnings growth forecast for next year|CGTX (Cognition Therapeutics) - Expected earnings per share growth for next year|IKT: Projected earnings per share increase next year|SAVA (Cassava) - Earnings growth forecast for next year|Assertio Therapeutics (ASRT) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year COYA|Expected earnings per share growth for next year vistagen.com VTGN|Net earnings per share growth forecast for next year Ovid Therapeutics OVID|Consensus forecast of earnings per share growth for next year Acumen Pharmaceuticals Inc. (ABOS)|CervoMed Inc - Earnings growth forecast for next year|Alterity Therapeutics (ATHE) - Expected earnings per share growth for next year|CLNN: Earnings growth forecast for next year|PepGen - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Jupiter Neurosciences Inc|RLMD: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Annovis Bio Corp (ANVS)|GRCE - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Firefly Neuroscience, Inc AIFF|KLTO: Projected earnings per share growth rate for next year|NeuroSense Therapeutics, Ltd. - Earnings growth forecast for next year|Expected net earnings per share growth next year Reviva Pharmaceuticals Holdings Inc.|MTVA (metaviatx.com) - Expected earnings per share growth for next year|NeurAxis Inc (NRXS) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Helius Medical Technologies, Inc.|PASG: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Neuphoria Therapeutics Inc. (NEUP)|NERV - Expected net earnings per share growth next year|Earnings growth forecast for next year ATHA (Athira)|ADXN - Expected earnings per share growth for next year|Alzamend - Earnings growth forecast for next year|Expected earnings per share trend next year CYCN (Cyclerion Therapeutics)|protagenic.com (PTIX) - Net earnings per share growth forecast for next year|Pasithea Therapeutics Corp. - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cortigent Inc|Expected net earnings per share growth next year Avenue Therapeutics Inc ATXI|Net earnings per share growth forecast for next year Brainstorm Cell (BCLI)|Expected earnings per share growth for next year caratherapeutics.com CARA|Net earnings per share growth forecast for next year Eliem Therapeutics Inc. ELYM|Intra-Cellular Therapies Inc. (ITCI) - Expected net earnings per share growth next year|Longboard Pharma - Earnings growth forecast for next year|Marinus Pharma (MRNS) - Expected earnings per share growth for next year|NKGN: Earnings growth forecast for next year|Expected net earnings per share growth next year neurobopharma.com (NRBO)|Net earnings per share growth forecast for next year Sage Therapeutics|Net earnings per share growth forecast for next year SNPX|Net earnings per share growth forecast for next year Trevena, Inc (TRVN)|Net earnings per share growth forecast for next year VIGL (vigilneuro.com)|Anew Medical - Expected earnings per share growth for next year|Expected earnings per share trend next year CERE
